1295-1297

Formal Total Synthesis of (–)-Emetine Using Catalytic Asymmetric Allylation of Cyclic Imines as a Key Step

Takashi Itoh,* Michiko Miyazaki, Hiromi Fukuoka, Kazuhiro Nagata, and Akio Ohsawa

School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan itoh-t@pharm.showa-u.ac.jp

Received December 14, 2005



Catalytic asymmetric allylation of 3,4-dinydro-6,7-dimethoxylsoquinoline was carried out using allyltrimethoxysilane in the presence of Cu(i) and tol-BINAP. The allyl adduct thus obtained was transformed to a chiral synthetic intermediate for (–)-emetine in good yield. The procedure was applied to the total synthesis of *ent*-emetine.

Isoquinoline alkaloids¹ have long attracted much attention due to their biological activities, which involve recent discoveries for α -glucosidase² and Parkinson's disease.³ Most of these compounds have a common characteristic in their structures; that is, they have a chiral center at the C-1 position of the isoquinoline nucleus. Thus, the formation of the chiral center is a crucial step for general synthetic methods of isoquinoline alkaloids.

There are, however, only a few methods^{4–6} for constructing a chiral 1-substituted tetrahydroisoquinoline nucleus in high stereoselectivity.

In the course of our research for the asymmetric synthesis of isoquinoline alkaloids, we have found that *N*-acylisoquinolinium salts with a chiral center in the acyl group underwent diastereoselective addition with allyltributyltin and silyl enol ethers to give 1-substituted tetrahydroisoquinoline derivatives in a stereoselective manner.⁷ These results prompted us to investigate a catalytic process for the reaction, and it was found that 3,4-dihydro-6,7-dimethoxyisoquinoline (1) was a substrate for the addition of allyltrimethoxysilane in the presence of a catalytic amount of Cu(I) salt and a chiral phosphine ligand to give 1-allyl-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline (2) in good yield and moderate stereoselectivity. The enantiomeric excess was further increased by recrystallization in the presence of dibenzoyl tartaric acid to afford a pure enantiomer. The allyl adduct thus obtained was transformed to a key intermediate for the total synthesis of (-)-emetine in short steps, and the *ent*-

^{(1) (}a) Rozwadowska, M. D. *Heterocycles* **1994**, *39*, 903. (b) Chrzanowska, M.; Rozwadowska, M. D. *Chem. Rev.* **2004**, *104*, 3341.

⁽²⁾ Takada, K.; Uehara, T.; Nakao, Y.; Matsunaga, S.; van Soest, R. W. M.; Fusetani, N. J. Am. Chem. Soc. 2004, 126, 187.

^{(3) (}a) Nagatsu, T. Neurosci. Res. **1997**, 29, 99. (b) Sano, T. J. Synth. Org. Chem. Jpn. **1999**, 57, 136. (c) Yamakawa, T.; Ohta, S. Biochem. Biophys. Res. Commun. **1997**, 236, 676. (d) Thull, U.; Kneubuler, S.; Gaillard, P.; Carrupt, P. A.; Testa, B.; Altomare, C.; Carotti, A.; Jenner, P.; McNaught, K. St. P. Biochem. Pharmacol. **1995**, 50, 869.

⁽⁴⁾ Meyers, A. I.; Dickman, D. A.; Boes, M. *Tetrahedron* **1987**, *43*, 5095 and references therein.

^{(5) (}a) Uematsu, N.; Fujii, A.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. **1996**, 118, 4916. (b) Noyori, R.; Hashiguchi, S. Acc. Chem. Res. **1997**, 30, 97.

^{(6) (}a) Taylor, M. S.; Jacobsen, E. N.J. Am. Chem. Soc. 2004, 126, 10558.
(b) Tayler, M. S.; Tokunaga, N.; Jacobsen, E. N. Angew. Chem., Int. Ed. 2005, 44, 2.

⁽⁷⁾ Itoh, T.; Nagata, K.; Miyazaki, M.; Kameoka, K.; Ohsawa, A. *Tetrahedron* **2001**, *57*, 8827 and references therein.

emetine was synthesized by the same method. This paper describes these results.

Although there are a few papers on the catalytic asymmetric allylation of imines,⁸ there has been no report concerning the catalytic allylation of cyclic imines.⁹ Although Yamamoto et al. recently reported a general method for the allylation of various kinds of imines, they showed the incompatibility of cyclic imines to their reaction system.^{8d} Recently, a new allylation reaction of ketones and aldehydes has been published by Shibasaki et al.¹⁰ using allyltrimethoxysilane and a catalytic amount of Cu(I) salt. We applied their reaction system to the allylation of 6,7-dimethoxy-3,4-dihydroisoquinoline and found that the reaction proceeded in a stereoselective manner as shown in Table 1.

Table	1				
MeO		CuCl-Chiral Ligand (10 mol 9 TBAT (10 mol %) Si(OMe) ₃ (2.0 equiv)		%) MeO	
MeO		solvent, t-BuOH, rt, ur	nder Ar	MeO ~	н,
	1	, , ,		2	2
					II
				yield of	ee of 2^{12}
entry	solvent	chiral ligand	time	2 (%)	(%)
1	THF		20 h	72	
2	THF	(R)-tol-BINAP	1 d	91	71(S)
3	THF	(R)-BINAP	1 d	35	71(S)
4	THF	(R,R)-DIPAMP	1 d	78	5
5	THF	(R,R)-CHIRAPHOS	1 d	31	21(S)
6	DMF	(R)-tol-BINAP	1 d	21	50(S)
7	ether	(R)-tol-BINAP	1 d	37	47(S)
8	dioxane	(R)-tol-BINAP	1 d	35	67 (S)

Various phosphine derivatives were investigated as chiral ligands, and it was found that tol-BINAP in THF at room temperature afforded the best result for the present reaction. The yield of **2** was lowered to 21% by the reaction at 10 °C without an increase of the ee, and the reaction did not proceed at 0 °C. Other allylation reagents such as allyltributyltin afforded a racemic product. Although the stereoselectivity is moderate, this is the first example that a cyclic imine is adopted as a catalytic allylation reaction.

The product **2** thus obtained was treated with (-)-dibenzoyl-L-tartaric acid to form a mixture of the diastereomeric salts, which was recrystallized from acetonitrile/H₂O (20:1) to give optically pure **2** (97% ee) in 67% yield based on the starting material.¹¹

(10) Yamasaki, S.; Fujii, K.; Wada, R.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2002, 124, 6536.

With a practical amount of compound 2 in hand, we decided to functionalize the obtained allyl group. After the protection of an amino group of 2, reaction of 3 with various monosubstituted alkenes using the second-generation Grubbs' catalyst was carried out, and it was found that the cross-metathesis products were obtained in high yields and good stereoselectivity.¹³ Without the Boc protecting group, the metathesis reaction did not proceed.

By using the ethyl acrylate, sufficient stereoselectivity was obtained to give an adequate amount of a functionalized (E)-alkene derivative **4** (Scheme 1).



The deprotection of **4** followed by Michael addition of **5** with methyl vinyl ketone afforded an *N*-(3-oxobutyl) derivative, which was then cyclized to **6** in a completely diastereoselective manner (Scheme 2). In our first plan, the acetyl group would be transformed to the corresponding ethyl group according to the reported method,¹⁴ but our attempt to reduce the keto group to give **7** resulted in a very low yield under various conditions.¹⁵

Thus, we changed the synthetic procedure as follows (Scheme 3). Although Michael addition of acrolein to compound **5** resulted in a complex mixture of the products, slowing the addition of acrolein considerably improved the reaction yield to a practical level. That is, the addition of acrolein to **5** over 5 h followed by treatment with pyrrolidine afforded a ring-closing product **8** in good yield and complete stereoselectivity. Although the compound **8** was obtained at first as its epimer at the C-3 position (according to emetine numbering), the epimeric compound rapidly isomerized to **8** under the reaction conditions. The formyl derivative **8** thus

^{(8) (}a) Nakamura, H.; Nakamura, K.; Yamamoto, Y.J. Am. Chem. Soc. 1998, 120, 4242. (b) Fang, X.; Johannsen, M.; Yao, S.; Gathergood, N.; Hazell, R. G.; Jorgensen, K. A. J. Org. Chem. 1999, 64, 4844. (c) Gastner, T.; Ishitani, H.; Akiyama, R.; Kobayashi, S. Angew. Chem., Int. Ed. 2001, 40, 1896. (d) Fernandes, R. A.; Stimac, A.; Yamamoto, Y. J. Am. Chem. Soc. 2003, 125, 14133.

⁽⁹⁾ There are a few reports which claimed the asymmetric allylation using a stoichiometrical amount of chiral compound; see: Nakamura, M.; Hirai, A.; Nakamura, E. J. Am. Chem. Soc. **1996**, *118*, 8489 and references therein.

⁽¹¹⁾ With three times of careful recrystallization, the tartrate salt of racemic 2 afforded the enantiomeric 2 in 97% ee.

⁽¹²⁾ The absolute configuration of the compound 2 was determined by the transformation to the known compound 10.

⁽¹³⁾ Nagata, K.; Itoh, T.; Fukuoka, H.; Nakamura, S.; Ohsawa, A. *Heterocycles* **2005**, *65*, 1283.

⁽¹⁴⁾ Hirai, Y.; Terada, T.; Hasegawa, A.; Yamazaki, T. Chem. Pharm. Bull. 1998, 36, 1343.

⁽¹⁵⁾ Other than the reported method that used ethanedithiol-TFA followed by Raney Ni, several reduction systems were tested which involve various variants of Wolff-Kishner or Clemmensen reduction, but the product **7** was not obtained in more than 7% yield.



obtained underwent the Wittig reaction with methyltriphenylphosphonium bromide followed by treatment with methanol to give alkene 9. A catalytic hydrogenation of 9 resulted in the formation of compound 10, which was reported by Tietze¹⁶ as an intermediate for the synthesis of (-)-emetine. Thus, the stereoselectivity of the present reaction was proved to be consistent with that of the natural product.

In our synthesis, the overall yield of **10** was 21.5% in 8 steps from the starting material **1**. Since the reported synthesis¹⁶ afforded **10** in 3.2% yield via 12 steps, the present



method gives a better way of obtaining the important intermediate **10**, which can also be transformed to several alkaloids such as psychotrine¹⁷ and tubulosine.¹⁸

The final stage of the total synthesis of (-)-emetine (11) was accomplished according to Tietze's method¹⁶ in three steps (Scheme 4).



Using the present procedure, we obtained *ent*-emetine ((+)-emetine) in overall yield of 8.5% from 1and (S)-tol-BINAP.

In this paper, we have described asymmetric formal total synthesis of (-)-emetine and the synthesis of (+)-emetine in a completely stereoselective manner. In the key step, catalytic allylation was carried out to introduce an allyl group at the C-1 position of the isoquinoline nucleus using tol-BINAP as a chiral source. The application of the allyl adduct 2 to the total synthesis of other isoquinoline alkaloids and the biological activity of *ent*-emetine are now under investigation.

Supporting Information Available: Detailed experimental procedures and spectral data for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL0530326

⁽¹⁶⁾ Tietze, L. F.; Rackelmann, N.; Sekar, G. Angew. Chem., Int. Ed. 2003, 42, 4254.

^{(17) (}a) Battersby, A. R.; Turner, J. C. J. Chem. Soc. 1960, 717. (b)
Teitel, S.; Brossi, A. J. Am. Chem. Soc. 1966, 88, 4068. (c) Fujii, T.; Ohba,
M.; Yonemitsu, O.; Ban, Y. Chem. Phar. Bull. 1982, 30, 598. (d) Fujii, T.;
Yamada, K.; Minami, S.; Yoshifuji, S.; Ohba, M. Chem. Pharm. Bull. 1983, 33, 144. (f)
Fujii, T.; Ohba, M. Chem. Pharm. Bull. 1985, 33, 583.

^{(18) (}a) Brauchli, P.; Deulofeu, V.; Budzikiewicz, H.; Djerassi, C. J. Am. Chem. Soc. **1964**, 86, 1895. (b) Openshaw, H. T.; Robson, N. C.; Whittaker, N. J. Chem. Soc. **1969**, 101. (c) Kametani, T.; Suzuki, Y.; Ihara, M. Can. J. Chem. **1979**, 57, 1679. (d) Ihara, M.; Yasui, K.; Taniguchi, N.; Fukumoto, K. J. Chem. Soc. **1990**, 1469. (e) Tietze, L. F.; Rackelmann, N.; Muller, I. Chem. Eur. J. **2004**, 10, 2722.